SCHEMBL25596402

SCHEMBL25596402

COC(=O)NC(CF)Cc1ccc(O)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PCNA P12004 1/20 0.50
▸ ESR1 P03372 2/20 0.49
▸ ESR2 Q92731 2/20 0.49
▸ MIF P14174 1/20 0.43
▸ CTRB1 P17538 2/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ FOLH1 Q04609 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ LNPEP Q9UIQ6 1/20 0.40
▸ MDM4 O15151 1/20 0.40
▸ MDM2 Q00987 1/20 0.40
▸ OPRD1 P41143 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ SLC7A5 Q01650 1/20 0.40
▸ ACACB O00763 1/20 0.40
▸ CTSS P25774 1/20 0.40
▸ CTSK P43235 1/20 0.40
▸ TAAR1 Q96RJ0 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25596288 0.86 PCNA (0.51) PCNAESR1ESR2MIFCTRB1
SCHEMBL25596407 0.84 ESR1 (0.47) PCNAESR1ESR2CTRB1FOLH1
SCHEMBL25596175 0.81 ESR1 (0.42) ESR1ESR2MIFOPRD1OPRK1
SCHEMBL25596399 0.79 ACACB (0.59) ESR1ESR2OPRD1OPRK1ACACB
SCHEMBL25596306 0.78 OPRK1 (0.42) ESR1ESR2OPRD1OPRK1SLC7A5
SCHEMBL13413401 0.76 FOLH1 (0.62) FOLH1TSHRLNPEPMDM4MDM2
SCHEMBL3389559 0.76 FOLH1 (0.62) FOLH1TSHRLNPEPMDM4MDM2
SCHEMBL22804066 0.76 FOLH1 (0.62) FOLH1TSHRLNPEPMDM4MDM2
SCHEMBL14274289 0.76 LNPEP (0.50) ESR1ESR2MIFKMT2ANPSR1
SCHEMBL2519897 0.76 NPSR1 (0.61) ESR1ESR2MIFKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181493-A1 BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME SENDA BIOSCIENCES INC (US) 2023-06-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181493-A1 BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME COMT, SNCA, PARK7 PCNA 4243/4885ESR1 4421/4885ESR2 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback